Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.
Identifieur interne : 000D44 ( PubMed/Checkpoint ); précédent : 000D43; suivant : 000D45Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.
Auteurs : Ira M. Jacobson [États-Unis] ; Eric Lawitz [États-Unis] ; Edward J. Gane [Nouvelle-Zélande] ; Bernard E. Willems [Canada] ; Peter J. Ruane [États-Unis] ; Ronald G. Nahass [États-Unis] ; Sergio M. Borgia [Canada] ; Stephen D. Shafran [Canada] ; Kimberly A. Workowski [Géorgie (pays)] ; Brian Pearlman [Géorgie (pays)] ; Robert H. Hyland [États-Unis] ; Luisa M. Stamm [États-Unis] ; Evguenia Svarovskaia [États-Unis] ; Hadas Dvory-Sobol [États-Unis] ; Yanni Zhu [États-Unis] ; G Mani Subramanian [États-Unis] ; Diana M. Brainard [États-Unis] ; John G. Mchutchison [États-Unis] ; Norbert Br U [États-Unis] ; Thomas Berg [Allemagne] ; Kosh Agarwal [Royaume-Uni] ; Bal Raj Bhandari [États-Unis] ; Mitchell Davis [États-Unis] ; Jordan J. Feld [Canada] ; Gregory J. Dore [Australie] ; Catherine A M. Stedman [Nouvelle-Zélande] ; Alexander J. Thompson [Australie] ; Tarik Asselah [France] ; Stuart K. Roberts [Australie] ; Graham R. Foster [Royaume-Uni]Source :
- Gastroenterology [ 1528-0012 ] ; 2017.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Antiviraux (administration et posologie), Antiviraux (effets indésirables), Antiviraux (usage thérapeutique), Association de médicaments, Carbamates (administration et posologie), Carbamates (effets indésirables), Carbamates (usage thérapeutique), Composés hétérocycliques avec 4 noyaux ou plus (administration et posologie), Composés hétérocycliques avec 4 noyaux ou plus (effets indésirables), Composés hétérocycliques avec 4 noyaux ou plus (usage thérapeutique), Composés macrocycliques (administration et posologie), Composés macrocycliques (effets indésirables), Composés macrocycliques (usage thérapeutique), Femelle, Humains, Hépatite C chronique (traitement médicamenteux), Jeune adulte, Mâle, Réponse virologique soutenue, Sofosbuvir (administration et posologie), Sofosbuvir (effets indésirables), Sofosbuvir (usage thérapeutique), Sujet âgé, Sujet âgé de 80 ans ou plus, Sulfonamides (administration et posologie), Sulfonamides (effets indésirables), Sulfonamides (usage thérapeutique).
- MESH :
- administration et posologie : Antiviraux, Carbamates, Composés hétérocycliques avec 4 noyaux ou plus, Composés macrocycliques, Sofosbuvir, Sulfonamides.
- effets indésirables : Antiviraux, Carbamates, Composés hétérocycliques avec 4 noyaux ou plus, Composés macrocycliques, Sofosbuvir, Sulfonamides.
- traitement médicamenteux : Hépatite C chronique.
- usage thérapeutique : Antiviraux, Carbamates, Composés hétérocycliques avec 4 noyaux ou plus, Composés macrocycliques, Sofosbuvir, Sulfonamides.
- Adolescent, Adulte, Adulte d'âge moyen, Association de médicaments, Femelle, Humains, Jeune adulte, Mâle, Réponse virologique soutenue, Sujet âgé, Sujet âgé de 80 ans ou plus.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Aged, 80 and over, Antiviral Agents (administration & dosage), Antiviral Agents (adverse effects), Antiviral Agents (therapeutic use), Carbamates (administration & dosage), Carbamates (adverse effects), Carbamates (therapeutic use), Drug Therapy, Combination, Female, Hepatitis C, Chronic (drug therapy), Heterocyclic Compounds, 4 or More Rings (administration & dosage), Heterocyclic Compounds, 4 or More Rings (adverse effects), Heterocyclic Compounds, 4 or More Rings (therapeutic use), Humans, Macrocyclic Compounds (administration & dosage), Macrocyclic Compounds (adverse effects), Macrocyclic Compounds (therapeutic use), Male, Middle Aged, Sofosbuvir (administration & dosage), Sofosbuvir (adverse effects), Sofosbuvir (therapeutic use), Sulfonamides (administration & dosage), Sulfonamides (adverse effects), Sulfonamides (therapeutic use), Sustained Virologic Response, Young Adult.
- MESH :
- chemical , administration & dosage : Antiviral Agents, Carbamates, Heterocyclic Compounds, 4 or More Rings, Macrocyclic Compounds, Sofosbuvir, Sulfonamides.
- chemical , adverse effects : Antiviral Agents, Carbamates, Heterocyclic Compounds, 4 or More Rings, Macrocyclic Compounds, Sofosbuvir, Sulfonamides.
- chemical , therapeutic use : Antiviral Agents, Carbamates, Heterocyclic Compounds, 4 or More Rings, Macrocyclic Compounds, Sofosbuvir, Sulfonamides.
- drug therapy : Hepatitis C, Chronic.
- Adolescent, Adult, Aged, Aged, 80 and over, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Sustained Virologic Response, Young Adult.
Abstract
Patients with chronic hepatitis C virus (HCV) infection have high rates of sustained virologic response (SVR) after 12 weeks of treatment with the nucleotide polymerase inhibitor sofosbuvir combined with the NS5A inhibitor velpatasvir. We assessed the efficacy of 8 weeks of treatment with sofosbuvir and velpatasvir plus the pangenotypic NS3/4A protease inhibitor voxilaprevir (sofosbuvir-velpatasvir-voxilaprevir).
DOI: 10.1053/j.gastro.2017.03.047
PubMed: 28390869
Affiliations:
- Allemagne, Australie, Canada, France, Géorgie (pays), Nouvelle-Zélande, Royaume-Uni, États-Unis
- Angleterre, Berlin, Californie, Floride, Grand Londres, Louisiane, New Jersey, Texas, État de New York
- Berlin, Londres
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:28390869Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.</title><author><name sortKey="Jacobson, Ira M" sort="Jacobson, Ira M" uniqKey="Jacobson I" first="Ira M" last="Jacobson">Ira M. Jacobson</name><affiliation wicri:level="2"><nlm:affiliation>Mount Sinai Beth Israel, New York, New York; Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: ira.jacobson@nyumc.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Mount Sinai Beth Israel, New York, New York; Icahn School of Medicine at Mount Sinai, New York</wicri:cityArea></affiliation></author><author><name sortKey="Lawitz, Eric" sort="Lawitz, Eric" uniqKey="Lawitz E" first="Eric" last="Lawitz">Eric Lawitz</name><affiliation wicri:level="2"><nlm:affiliation>Texas Liver Institute, University of Texas Health Science Center, San Antonio, Texas.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Texas Liver Institute, University of Texas Health Science Center, San Antonio</wicri:cityArea></affiliation></author><author><name sortKey="Gane, Edward J" sort="Gane, Edward J" uniqKey="Gane E" first="Edward J" last="Gane">Edward J. Gane</name><affiliation wicri:level="1"><nlm:affiliation>New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand.</nlm:affiliation><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland</wicri:regionArea><wicri:noRegion>Auckland</wicri:noRegion></affiliation></author><author><name sortKey="Willems, Bernard E" sort="Willems, Bernard E" uniqKey="Willems B" first="Bernard E" last="Willems">Bernard E. Willems</name><affiliation wicri:level="1"><nlm:affiliation>Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre Hospitalier de l'Université de Montréal, Montréal, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Ruane, Peter J" sort="Ruane, Peter J" uniqKey="Ruane P" first="Peter J" last="Ruane">Peter J. Ruane</name><affiliation wicri:level="2"><nlm:affiliation>Ruane Medical and Liver Health Institute, Los Angeles, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Ruane Medical and Liver Health Institute, Los Angeles</wicri:cityArea></affiliation></author><author><name sortKey="Nahass, Ronald G" sort="Nahass, Ronald G" uniqKey="Nahass R" first="Ronald G" last="Nahass">Ronald G. Nahass</name><affiliation wicri:level="2"><nlm:affiliation>ID Care, Hillsborough, New Jersey.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>ID Care, Hillsborough</wicri:cityArea></affiliation></author><author><name sortKey="Borgia, Sergio M" sort="Borgia, Sergio M" uniqKey="Borgia S" first="Sergio M" last="Borgia">Sergio M. Borgia</name><affiliation wicri:level="1"><nlm:affiliation>William Osler Health System, Brampton Civic Hospital, Brampton, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>William Osler Health System, Brampton Civic Hospital, Brampton, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Shafran, Stephen D" sort="Shafran, Stephen D" uniqKey="Shafran S" first="Stephen D" last="Shafran">Stephen D. Shafran</name><affiliation wicri:level="1"><nlm:affiliation>University of Alberta, Edmonton, Alberta, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>University of Alberta, Edmonton, Alberta</wicri:regionArea><wicri:noRegion>Alberta</wicri:noRegion></affiliation></author><author><name sortKey="Workowski, Kimberly A" sort="Workowski, Kimberly A" uniqKey="Workowski K" first="Kimberly A" last="Workowski">Kimberly A. Workowski</name><affiliation wicri:level="1"><nlm:affiliation>Emory University, Atlanta, Georgia.</nlm:affiliation><country xml:lang="fr">Géorgie (pays)</country><wicri:regionArea>Emory University, Atlanta</wicri:regionArea><wicri:noRegion>Atlanta</wicri:noRegion></affiliation></author><author><name sortKey="Pearlman, Brian" sort="Pearlman, Brian" uniqKey="Pearlman B" first="Brian" last="Pearlman">Brian Pearlman</name><affiliation wicri:level="1"><nlm:affiliation>Atlanta Medical Center, Atlanta, Georgia.</nlm:affiliation><country xml:lang="fr">Géorgie (pays)</country><wicri:regionArea>Atlanta Medical Center, Atlanta</wicri:regionArea><wicri:noRegion>Atlanta</wicri:noRegion></affiliation></author><author><name sortKey="Hyland, Robert H" sort="Hyland, Robert H" uniqKey="Hyland R" first="Robert H" last="Hyland">Robert H. Hyland</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Inc, Foster City, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Gilead Sciences, Inc, Foster City</wicri:cityArea></affiliation></author><author><name sortKey="Stamm, Luisa M" sort="Stamm, Luisa M" uniqKey="Stamm L" first="Luisa M" last="Stamm">Luisa M. Stamm</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Inc, Foster City, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Gilead Sciences, Inc, Foster City</wicri:cityArea></affiliation></author><author><name sortKey="Svarovskaia, Evguenia" sort="Svarovskaia, Evguenia" uniqKey="Svarovskaia E" first="Evguenia" last="Svarovskaia">Evguenia Svarovskaia</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Inc, Foster City, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Gilead Sciences, Inc, Foster City</wicri:cityArea></affiliation></author><author><name sortKey="Dvory Sobol, Hadas" sort="Dvory Sobol, Hadas" uniqKey="Dvory Sobol H" first="Hadas" last="Dvory-Sobol">Hadas Dvory-Sobol</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Inc, Foster City, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Gilead Sciences, Inc, Foster City</wicri:cityArea></affiliation></author><author><name sortKey="Zhu, Yanni" sort="Zhu, Yanni" uniqKey="Zhu Y" first="Yanni" last="Zhu">Yanni Zhu</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Inc, Foster City, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Gilead Sciences, Inc, Foster City</wicri:cityArea></affiliation></author><author><name sortKey="Subramanian, G Mani" sort="Subramanian, G Mani" uniqKey="Subramanian G" first="G Mani" last="Subramanian">G Mani Subramanian</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Inc, Foster City, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Gilead Sciences, Inc, Foster City</wicri:cityArea></affiliation></author><author><name sortKey="Brainard, Diana M" sort="Brainard, Diana M" uniqKey="Brainard D" first="Diana M" last="Brainard">Diana M. Brainard</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Inc, Foster City, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Gilead Sciences, Inc, Foster City</wicri:cityArea></affiliation></author><author><name sortKey="Mchutchison, John G" sort="Mchutchison, John G" uniqKey="Mchutchison J" first="John G" last="Mchutchison">John G. Mchutchison</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Inc, Foster City, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Gilead Sciences, Inc, Foster City</wicri:cityArea></affiliation></author><author><name sortKey="Br U, Norbert" sort="Br U, Norbert" uniqKey="Br U N" first="Norbert" last="Br U">Norbert Br U</name><affiliation wicri:level="2"><nlm:affiliation>James J. Peters Veterans Affairs Medical Center, Bronx, New York; Icahn School of Medicine at Mount Sinai, New York, New York.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>James J. Peters Veterans Affairs Medical Center, Bronx, New York; Icahn School of Medicine at Mount Sinai, New York</wicri:cityArea></affiliation></author><author><name sortKey="Berg, Thomas" sort="Berg, Thomas" uniqKey="Berg T" first="Thomas" last="Berg">Thomas Berg</name><affiliation wicri:level="3"><nlm:affiliation>Medical Department of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Medical Department of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Agarwal, Kosh" sort="Agarwal, Kosh" uniqKey="Agarwal K" first="Kosh" last="Agarwal">Kosh Agarwal</name><affiliation wicri:level="3"><nlm:affiliation>Institute of Liver Studies, Kings College Hospital, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Liver Studies, Kings College Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Bhandari, Bal Raj" sort="Bhandari, Bal Raj" uniqKey="Bhandari B" first="Bal Raj" last="Bhandari">Bal Raj Bhandari</name><affiliation wicri:level="2"><nlm:affiliation>Gastroenterology and Nutritional Medical Services, Bastrop, Louisiana.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Louisiane</region></placeName><wicri:cityArea>Gastroenterology and Nutritional Medical Services, Bastrop</wicri:cityArea></affiliation></author><author><name sortKey="Davis, Mitchell" sort="Davis, Mitchell" uniqKey="Davis M" first="Mitchell" last="Davis">Mitchell Davis</name><affiliation wicri:level="2"><nlm:affiliation>Digestive Care, South Florida Center of Gastroenterology, Wellington, Florida.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Floride</region></placeName><wicri:cityArea>Digestive Care, South Florida Center of Gastroenterology, Wellington</wicri:cityArea></affiliation></author><author><name sortKey="Feld, Jordan J" sort="Feld, Jordan J" uniqKey="Feld J" first="Jordan J" last="Feld">Jordan J. Feld</name><affiliation wicri:level="1"><nlm:affiliation>Toronto Western Hospital Liver Centre, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Toronto Western Hospital Liver Centre, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Dore, Gregory J" sort="Dore, Gregory J" uniqKey="Dore G" first="Gregory J" last="Dore">Gregory J. Dore</name><affiliation wicri:level="1"><nlm:affiliation>St Vincent's Hospital Sydney, University of New South Wales Sydney, Sydney, New South Wales, Australia; Kirby Institute, University of New South Wales Sydney, Sydney, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>St Vincent's Hospital Sydney, University of New South Wales Sydney, Sydney, New South Wales, Australia; Kirby Institute, University of New South Wales Sydney, Sydney, New South Wales</wicri:regionArea><wicri:noRegion>New South Wales</wicri:noRegion></affiliation></author><author><name sortKey="Stedman, Catherine A M" sort="Stedman, Catherine A M" uniqKey="Stedman C" first="Catherine A M" last="Stedman">Catherine A M. Stedman</name><affiliation wicri:level="1"><nlm:affiliation>Christchurch Hospital, University of Otago, Christchurch, New Zealand.</nlm:affiliation><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>Christchurch Hospital, University of Otago, Christchurch</wicri:regionArea><wicri:noRegion>Christchurch</wicri:noRegion></affiliation></author><author><name sortKey="Thompson, Alexander J" sort="Thompson, Alexander J" uniqKey="Thompson A" first="Alexander J" last="Thompson">Alexander J. Thompson</name><affiliation wicri:level="1"><nlm:affiliation>St. Vincent's Hospital, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>St. Vincent's Hospital, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Asselah, Tarik" sort="Asselah, Tarik" uniqKey="Asselah T" first="Tarik" last="Asselah">Tarik Asselah</name><affiliation wicri:level="1"><nlm:affiliation>Hôpital Beaujon, Université Paris Diderot, INSERM UMR 1149, Centre de Recherche sur l'Inflammation, Clichy, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Beaujon, Université Paris Diderot, INSERM UMR 1149, Centre de Recherche sur l'Inflammation, Clichy</wicri:regionArea><wicri:noRegion>Clichy</wicri:noRegion><wicri:noRegion>Clichy</wicri:noRegion></affiliation></author><author><name sortKey="Roberts, Stuart K" sort="Roberts, Stuart K" uniqKey="Roberts S" first="Stuart K" last="Roberts">Stuart K. Roberts</name><affiliation wicri:level="1"><nlm:affiliation>Alfred Hospital, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Alfred Hospital, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Foster, Graham R" sort="Foster, Graham R" uniqKey="Foster G" first="Graham R" last="Foster">Graham R. Foster</name><affiliation wicri:level="3"><nlm:affiliation>Royal London Hospital, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Royal London Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28390869</idno><idno type="pmid">28390869</idno><idno type="doi">10.1053/j.gastro.2017.03.047</idno><idno type="wicri:Area/PubMed/Corpus">000912</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000912</idno><idno type="wicri:Area/PubMed/Curation">000909</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000909</idno><idno type="wicri:Area/PubMed/Checkpoint">000909</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000909</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.</title><author><name sortKey="Jacobson, Ira M" sort="Jacobson, Ira M" uniqKey="Jacobson I" first="Ira M" last="Jacobson">Ira M. Jacobson</name><affiliation wicri:level="2"><nlm:affiliation>Mount Sinai Beth Israel, New York, New York; Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: ira.jacobson@nyumc.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Mount Sinai Beth Israel, New York, New York; Icahn School of Medicine at Mount Sinai, New York</wicri:cityArea></affiliation></author><author><name sortKey="Lawitz, Eric" sort="Lawitz, Eric" uniqKey="Lawitz E" first="Eric" last="Lawitz">Eric Lawitz</name><affiliation wicri:level="2"><nlm:affiliation>Texas Liver Institute, University of Texas Health Science Center, San Antonio, Texas.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Texas Liver Institute, University of Texas Health Science Center, San Antonio</wicri:cityArea></affiliation></author><author><name sortKey="Gane, Edward J" sort="Gane, Edward J" uniqKey="Gane E" first="Edward J" last="Gane">Edward J. Gane</name><affiliation wicri:level="1"><nlm:affiliation>New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand.</nlm:affiliation><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland</wicri:regionArea><wicri:noRegion>Auckland</wicri:noRegion></affiliation></author><author><name sortKey="Willems, Bernard E" sort="Willems, Bernard E" uniqKey="Willems B" first="Bernard E" last="Willems">Bernard E. Willems</name><affiliation wicri:level="1"><nlm:affiliation>Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre Hospitalier de l'Université de Montréal, Montréal, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Ruane, Peter J" sort="Ruane, Peter J" uniqKey="Ruane P" first="Peter J" last="Ruane">Peter J. Ruane</name><affiliation wicri:level="2"><nlm:affiliation>Ruane Medical and Liver Health Institute, Los Angeles, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Ruane Medical and Liver Health Institute, Los Angeles</wicri:cityArea></affiliation></author><author><name sortKey="Nahass, Ronald G" sort="Nahass, Ronald G" uniqKey="Nahass R" first="Ronald G" last="Nahass">Ronald G. Nahass</name><affiliation wicri:level="2"><nlm:affiliation>ID Care, Hillsborough, New Jersey.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>ID Care, Hillsborough</wicri:cityArea></affiliation></author><author><name sortKey="Borgia, Sergio M" sort="Borgia, Sergio M" uniqKey="Borgia S" first="Sergio M" last="Borgia">Sergio M. Borgia</name><affiliation wicri:level="1"><nlm:affiliation>William Osler Health System, Brampton Civic Hospital, Brampton, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>William Osler Health System, Brampton Civic Hospital, Brampton, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Shafran, Stephen D" sort="Shafran, Stephen D" uniqKey="Shafran S" first="Stephen D" last="Shafran">Stephen D. Shafran</name><affiliation wicri:level="1"><nlm:affiliation>University of Alberta, Edmonton, Alberta, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>University of Alberta, Edmonton, Alberta</wicri:regionArea><wicri:noRegion>Alberta</wicri:noRegion></affiliation></author><author><name sortKey="Workowski, Kimberly A" sort="Workowski, Kimberly A" uniqKey="Workowski K" first="Kimberly A" last="Workowski">Kimberly A. Workowski</name><affiliation wicri:level="1"><nlm:affiliation>Emory University, Atlanta, Georgia.</nlm:affiliation><country xml:lang="fr">Géorgie (pays)</country><wicri:regionArea>Emory University, Atlanta</wicri:regionArea><wicri:noRegion>Atlanta</wicri:noRegion></affiliation></author><author><name sortKey="Pearlman, Brian" sort="Pearlman, Brian" uniqKey="Pearlman B" first="Brian" last="Pearlman">Brian Pearlman</name><affiliation wicri:level="1"><nlm:affiliation>Atlanta Medical Center, Atlanta, Georgia.</nlm:affiliation><country xml:lang="fr">Géorgie (pays)</country><wicri:regionArea>Atlanta Medical Center, Atlanta</wicri:regionArea><wicri:noRegion>Atlanta</wicri:noRegion></affiliation></author><author><name sortKey="Hyland, Robert H" sort="Hyland, Robert H" uniqKey="Hyland R" first="Robert H" last="Hyland">Robert H. Hyland</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Inc, Foster City, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Gilead Sciences, Inc, Foster City</wicri:cityArea></affiliation></author><author><name sortKey="Stamm, Luisa M" sort="Stamm, Luisa M" uniqKey="Stamm L" first="Luisa M" last="Stamm">Luisa M. Stamm</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Inc, Foster City, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Gilead Sciences, Inc, Foster City</wicri:cityArea></affiliation></author><author><name sortKey="Svarovskaia, Evguenia" sort="Svarovskaia, Evguenia" uniqKey="Svarovskaia E" first="Evguenia" last="Svarovskaia">Evguenia Svarovskaia</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Inc, Foster City, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Gilead Sciences, Inc, Foster City</wicri:cityArea></affiliation></author><author><name sortKey="Dvory Sobol, Hadas" sort="Dvory Sobol, Hadas" uniqKey="Dvory Sobol H" first="Hadas" last="Dvory-Sobol">Hadas Dvory-Sobol</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Inc, Foster City, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Gilead Sciences, Inc, Foster City</wicri:cityArea></affiliation></author><author><name sortKey="Zhu, Yanni" sort="Zhu, Yanni" uniqKey="Zhu Y" first="Yanni" last="Zhu">Yanni Zhu</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Inc, Foster City, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Gilead Sciences, Inc, Foster City</wicri:cityArea></affiliation></author><author><name sortKey="Subramanian, G Mani" sort="Subramanian, G Mani" uniqKey="Subramanian G" first="G Mani" last="Subramanian">G Mani Subramanian</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Inc, Foster City, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Gilead Sciences, Inc, Foster City</wicri:cityArea></affiliation></author><author><name sortKey="Brainard, Diana M" sort="Brainard, Diana M" uniqKey="Brainard D" first="Diana M" last="Brainard">Diana M. Brainard</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Inc, Foster City, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Gilead Sciences, Inc, Foster City</wicri:cityArea></affiliation></author><author><name sortKey="Mchutchison, John G" sort="Mchutchison, John G" uniqKey="Mchutchison J" first="John G" last="Mchutchison">John G. Mchutchison</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Inc, Foster City, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Gilead Sciences, Inc, Foster City</wicri:cityArea></affiliation></author><author><name sortKey="Br U, Norbert" sort="Br U, Norbert" uniqKey="Br U N" first="Norbert" last="Br U">Norbert Br U</name><affiliation wicri:level="2"><nlm:affiliation>James J. Peters Veterans Affairs Medical Center, Bronx, New York; Icahn School of Medicine at Mount Sinai, New York, New York.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>James J. Peters Veterans Affairs Medical Center, Bronx, New York; Icahn School of Medicine at Mount Sinai, New York</wicri:cityArea></affiliation></author><author><name sortKey="Berg, Thomas" sort="Berg, Thomas" uniqKey="Berg T" first="Thomas" last="Berg">Thomas Berg</name><affiliation wicri:level="3"><nlm:affiliation>Medical Department of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Medical Department of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Agarwal, Kosh" sort="Agarwal, Kosh" uniqKey="Agarwal K" first="Kosh" last="Agarwal">Kosh Agarwal</name><affiliation wicri:level="3"><nlm:affiliation>Institute of Liver Studies, Kings College Hospital, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Liver Studies, Kings College Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Bhandari, Bal Raj" sort="Bhandari, Bal Raj" uniqKey="Bhandari B" first="Bal Raj" last="Bhandari">Bal Raj Bhandari</name><affiliation wicri:level="2"><nlm:affiliation>Gastroenterology and Nutritional Medical Services, Bastrop, Louisiana.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Louisiane</region></placeName><wicri:cityArea>Gastroenterology and Nutritional Medical Services, Bastrop</wicri:cityArea></affiliation></author><author><name sortKey="Davis, Mitchell" sort="Davis, Mitchell" uniqKey="Davis M" first="Mitchell" last="Davis">Mitchell Davis</name><affiliation wicri:level="2"><nlm:affiliation>Digestive Care, South Florida Center of Gastroenterology, Wellington, Florida.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Floride</region></placeName><wicri:cityArea>Digestive Care, South Florida Center of Gastroenterology, Wellington</wicri:cityArea></affiliation></author><author><name sortKey="Feld, Jordan J" sort="Feld, Jordan J" uniqKey="Feld J" first="Jordan J" last="Feld">Jordan J. Feld</name><affiliation wicri:level="1"><nlm:affiliation>Toronto Western Hospital Liver Centre, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Toronto Western Hospital Liver Centre, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Dore, Gregory J" sort="Dore, Gregory J" uniqKey="Dore G" first="Gregory J" last="Dore">Gregory J. Dore</name><affiliation wicri:level="1"><nlm:affiliation>St Vincent's Hospital Sydney, University of New South Wales Sydney, Sydney, New South Wales, Australia; Kirby Institute, University of New South Wales Sydney, Sydney, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>St Vincent's Hospital Sydney, University of New South Wales Sydney, Sydney, New South Wales, Australia; Kirby Institute, University of New South Wales Sydney, Sydney, New South Wales</wicri:regionArea><wicri:noRegion>New South Wales</wicri:noRegion></affiliation></author><author><name sortKey="Stedman, Catherine A M" sort="Stedman, Catherine A M" uniqKey="Stedman C" first="Catherine A M" last="Stedman">Catherine A M. Stedman</name><affiliation wicri:level="1"><nlm:affiliation>Christchurch Hospital, University of Otago, Christchurch, New Zealand.</nlm:affiliation><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>Christchurch Hospital, University of Otago, Christchurch</wicri:regionArea><wicri:noRegion>Christchurch</wicri:noRegion></affiliation></author><author><name sortKey="Thompson, Alexander J" sort="Thompson, Alexander J" uniqKey="Thompson A" first="Alexander J" last="Thompson">Alexander J. Thompson</name><affiliation wicri:level="1"><nlm:affiliation>St. Vincent's Hospital, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>St. Vincent's Hospital, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Asselah, Tarik" sort="Asselah, Tarik" uniqKey="Asselah T" first="Tarik" last="Asselah">Tarik Asselah</name><affiliation wicri:level="1"><nlm:affiliation>Hôpital Beaujon, Université Paris Diderot, INSERM UMR 1149, Centre de Recherche sur l'Inflammation, Clichy, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Beaujon, Université Paris Diderot, INSERM UMR 1149, Centre de Recherche sur l'Inflammation, Clichy</wicri:regionArea><wicri:noRegion>Clichy</wicri:noRegion><wicri:noRegion>Clichy</wicri:noRegion></affiliation></author><author><name sortKey="Roberts, Stuart K" sort="Roberts, Stuart K" uniqKey="Roberts S" first="Stuart K" last="Roberts">Stuart K. Roberts</name><affiliation wicri:level="1"><nlm:affiliation>Alfred Hospital, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Alfred Hospital, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Foster, Graham R" sort="Foster, Graham R" uniqKey="Foster G" first="Graham R" last="Foster">Graham R. Foster</name><affiliation wicri:level="3"><nlm:affiliation>Royal London Hospital, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Royal London Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></analytic><series><title level="j">Gastroenterology</title><idno type="eISSN">1528-0012</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antiviral Agents (administration & dosage)</term><term>Antiviral Agents (adverse effects)</term><term>Antiviral Agents (therapeutic use)</term><term>Carbamates (administration & dosage)</term><term>Carbamates (adverse effects)</term><term>Carbamates (therapeutic use)</term><term>Drug Therapy, Combination</term><term>Female</term><term>Hepatitis C, Chronic (drug therapy)</term><term>Heterocyclic Compounds, 4 or More Rings (administration & dosage)</term><term>Heterocyclic Compounds, 4 or More Rings (adverse effects)</term><term>Heterocyclic Compounds, 4 or More Rings (therapeutic use)</term><term>Humans</term><term>Macrocyclic Compounds (administration & dosage)</term><term>Macrocyclic Compounds (adverse effects)</term><term>Macrocyclic Compounds (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Sofosbuvir (administration & dosage)</term><term>Sofosbuvir (adverse effects)</term><term>Sofosbuvir (therapeutic use)</term><term>Sulfonamides (administration & dosage)</term><term>Sulfonamides (adverse effects)</term><term>Sulfonamides (therapeutic use)</term><term>Sustained Virologic Response</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Antiviraux (administration et posologie)</term><term>Antiviraux (effets indésirables)</term><term>Antiviraux (usage thérapeutique)</term><term>Association de médicaments</term><term>Carbamates (administration et posologie)</term><term>Carbamates (effets indésirables)</term><term>Carbamates (usage thérapeutique)</term><term>Composés hétérocycliques avec 4 noyaux ou plus (administration et posologie)</term><term>Composés hétérocycliques avec 4 noyaux ou plus (effets indésirables)</term><term>Composés hétérocycliques avec 4 noyaux ou plus (usage thérapeutique)</term><term>Composés macrocycliques (administration et posologie)</term><term>Composés macrocycliques (effets indésirables)</term><term>Composés macrocycliques (usage thérapeutique)</term><term>Femelle</term><term>Humains</term><term>Hépatite C chronique (traitement médicamenteux)</term><term>Jeune adulte</term><term>Mâle</term><term>Réponse virologique soutenue</term><term>Sofosbuvir (administration et posologie)</term><term>Sofosbuvir (effets indésirables)</term><term>Sofosbuvir (usage thérapeutique)</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Sulfonamides (administration et posologie)</term><term>Sulfonamides (effets indésirables)</term><term>Sulfonamides (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiviral Agents</term><term>Carbamates</term><term>Heterocyclic Compounds, 4 or More Rings</term><term>Macrocyclic Compounds</term><term>Sofosbuvir</term><term>Sulfonamides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiviral Agents</term><term>Carbamates</term><term>Heterocyclic Compounds, 4 or More Rings</term><term>Macrocyclic Compounds</term><term>Sofosbuvir</term><term>Sulfonamides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Carbamates</term><term>Heterocyclic Compounds, 4 or More Rings</term><term>Macrocyclic Compounds</term><term>Sofosbuvir</term><term>Sulfonamides</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antiviraux</term><term>Carbamates</term><term>Composés hétérocycliques avec 4 noyaux ou plus</term><term>Composés macrocycliques</term><term>Sofosbuvir</term><term>Sulfonamides</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hepatitis C, Chronic</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antiviraux</term><term>Carbamates</term><term>Composés hétérocycliques avec 4 noyaux ou plus</term><term>Composés macrocycliques</term><term>Sofosbuvir</term><term>Sulfonamides</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Hépatite C chronique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Carbamates</term><term>Composés hétérocycliques avec 4 noyaux ou plus</term><term>Composés macrocycliques</term><term>Sofosbuvir</term><term>Sulfonamides</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Sustained Virologic Response</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Association de médicaments</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Réponse virologique soutenue</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Patients with chronic hepatitis C virus (HCV) infection have high rates of sustained virologic response (SVR) after 12 weeks of treatment with the nucleotide polymerase inhibitor sofosbuvir combined with the NS5A inhibitor velpatasvir. We assessed the efficacy of 8 weeks of treatment with sofosbuvir and velpatasvir plus the pangenotypic NS3/4A protease inhibitor voxilaprevir (sofosbuvir-velpatasvir-voxilaprevir).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28390869</PMID><DateCreated><Year>2017</Year><Month>04</Month><Day>09</Day></DateCreated><DateCompleted><Year>2017</Year><Month>09</Month><Day>05</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1528-0012</ISSN><JournalIssue CitedMedium="Internet"><Volume>153</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Gastroenterology</Title><ISOAbbreviation>Gastroenterology</ISOAbbreviation></Journal><ArticleTitle>Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.</ArticleTitle><Pagination><MedlinePgn>113-122</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0016-5085(17)35399-4</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1053/j.gastro.2017.03.047</ELocationID><Abstract><AbstractText Label="BACKGROUND & AIMS" NlmCategory="OBJECTIVE">Patients with chronic hepatitis C virus (HCV) infection have high rates of sustained virologic response (SVR) after 12 weeks of treatment with the nucleotide polymerase inhibitor sofosbuvir combined with the NS5A inhibitor velpatasvir. We assessed the efficacy of 8 weeks of treatment with sofosbuvir and velpatasvir plus the pangenotypic NS3/4A protease inhibitor voxilaprevir (sofosbuvir-velpatasvir-voxilaprevir).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In 2 phase 3, open-label trials, patients with HCV infection who had not been treated previously with a direct-acting antiviral agent were assigned randomly to groups given sofosbuvir-velpatasvir-voxilaprevir for 8 weeks or sofosbuvir-velpatasvir for 12 weeks. POLARIS-2, which enrolled patients infected with all HCV genotypes with or without cirrhosis, except patients with genotype 3 and cirrhosis, was designed to test the noninferiority of 8 weeks of sofosbuvir-velpatasvir-voxilaprevir to 12 weeks of sofosbuvir-velpatasvir using a noninferiority margin of 5%. POLARIS-3, which enrolled patients infected with HCV genotype 3 who had cirrhosis, compared rates of SVR in both groups with a performance goal of 83%.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In POLARIS-2, 95% (95% confidence interval [CI], 93%-97%) of patients had an SVR to 8 weeks of sofosbuvir-velpatasvir-voxilaprevir; this did not meet the criterion to establish noninferiority to 12 weeks of sofosbuvir-velpatasvir, which produced an SVR in 98% of patients (95% CI, 96%-99%; difference in the stratum-adjusted Mantel-Haenszel proportions of -3.2%; 95% CI, -6.0% to -0.4%). The difference in the efficacy was owing primarily to a lower rate of SVR (92%) among patients with HCV genotype 1a infection receiving 8 weeks of sofosbuvir-velpatasvir-voxilaprevir. In POLARIS-3, 96% of patients (95% CI, 91%-99%) achieved an SVR in both treatment groups, which was significantly superior to the performance goal. Overall, the most common adverse events were headache, fatigue, diarrhea, and nausea; diarrhea and nausea were reported more frequently by patients receiving voxilaprevir. In both trials, the proportion of patients who discontinued treatment because of adverse events was low (range, 0%-1%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In phase 3 trials of patients with HCV infection, we did not establish that sofosbuvir-velpatasvir-voxilaprevir for 8 weeks was noninferior to sofosbuvir-velpatasvir for 12 weeks, but the 2 regimens had similar rates of SVR in patients with HCV genotype 3 and cirrhosis. Mild gastrointestinal adverse events were associated with treatment regimens that included voxilaprevir. ClinicalTrials.gov numbers: POLARIS-2, NCT02607800; and POLARIS-3, NCT02639338.</AbstractText><CopyrightInformation>Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jacobson</LastName><ForeName>Ira M</ForeName><Initials>IM</Initials><AffiliationInfo><Affiliation>Mount Sinai Beth Israel, New York, New York; Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: ira.jacobson@nyumc.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lawitz</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Texas Liver Institute, University of Texas Health Science Center, San Antonio, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gane</LastName><ForeName>Edward J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willems</LastName><ForeName>Bernard E</ForeName><Initials>BE</Initials><AffiliationInfo><Affiliation>Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruane</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Ruane Medical and Liver Health Institute, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nahass</LastName><ForeName>Ronald G</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>ID Care, Hillsborough, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borgia</LastName><ForeName>Sergio M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>William Osler Health System, Brampton Civic Hospital, Brampton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shafran</LastName><ForeName>Stephen D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>University of Alberta, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Workowski</LastName><ForeName>Kimberly A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pearlman</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Atlanta Medical Center, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyland</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Inc, Foster City, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stamm</LastName><ForeName>Luisa M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Inc, Foster City, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Svarovskaia</LastName><ForeName>Evguenia</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Inc, Foster City, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dvory-Sobol</LastName><ForeName>Hadas</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Inc, Foster City, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Yanni</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Inc, Foster City, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subramanian</LastName><ForeName>G Mani</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Inc, Foster City, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brainard</LastName><ForeName>Diana M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Inc, Foster City, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McHutchison</LastName><ForeName>John G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Inc, Foster City, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bräu</LastName><ForeName>Norbert</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>James J. Peters Veterans Affairs Medical Center, Bronx, New York; Icahn School of Medicine at Mount Sinai, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berg</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Medical Department of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agarwal</LastName><ForeName>Kosh</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Liver Studies, Kings College Hospital, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhandari</LastName><ForeName>Bal Raj</ForeName><Initials>BR</Initials><AffiliationInfo><Affiliation>Gastroenterology and Nutritional Medical Services, Bastrop, Louisiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Mitchell</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Digestive Care, South Florida Center of Gastroenterology, Wellington, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feld</LastName><ForeName>Jordan J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Toronto Western Hospital Liver Centre, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dore</LastName><ForeName>Gregory J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>St Vincent's Hospital Sydney, University of New South Wales Sydney, Sydney, New South Wales, Australia; Kirby Institute, University of New South Wales Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stedman</LastName><ForeName>Catherine A M</ForeName><Initials>CAM</Initials><AffiliationInfo><Affiliation>Christchurch Hospital, University of Otago, Christchurch, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Alexander J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>St. Vincent's Hospital, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asselah</LastName><ForeName>Tarik</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Hôpital Beaujon, Université Paris Diderot, INSERM UMR 1149, Centre de Recherche sur l'Inflammation, Clichy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Stuart K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Alfred Hospital, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foster</LastName><ForeName>Graham R</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>Royal London Hospital, London, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>04</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Gastroenterology</MedlineTA><NlmUniqueID>0374630</NlmUniqueID><ISSNLinking>0016-5085</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002219">Carbamates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006576">Heterocyclic Compounds, 4 or More Rings</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047028">Macrocyclic Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000604171">velpatasvir</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000619503">voxilaprevir</NameOfSubstance></Chemical><Chemical><RegistryNumber>WJ6CA3ZU8B</RegistryNumber><NameOfSubstance UI="D000069474">Sofosbuvir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002219" MajorTopicYN="N">Carbamates</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006576" MajorTopicYN="N">Heterocyclic Compounds, 4 or More Rings</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047028" MajorTopicYN="N">Macrocyclic Compounds</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069474" MajorTopicYN="N">Sofosbuvir</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072230" MajorTopicYN="N">Sustained Virologic Response</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical Trial</Keyword><Keyword MajorTopicYN="N">Comparison</Keyword><Keyword MajorTopicYN="N">Direct-Acting Antiviral Agent</Keyword><Keyword MajorTopicYN="N">Shortened Duration Therapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>02</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>03</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>03</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28390869</ArticleId><ArticleId IdType="pii">S0016-5085(17)35399-4</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2017.03.047</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Canada</li><li>France</li><li>Géorgie (pays)</li><li>Nouvelle-Zélande</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Berlin</li><li>Californie</li><li>Floride</li><li>Grand Londres</li><li>Louisiane</li><li>New Jersey</li><li>Texas</li><li>État de New York</li></region><settlement><li>Berlin</li><li>Londres</li></settlement></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Jacobson, Ira M" sort="Jacobson, Ira M" uniqKey="Jacobson I" first="Ira M" last="Jacobson">Ira M. Jacobson</name></region><name sortKey="Bhandari, Bal Raj" sort="Bhandari, Bal Raj" uniqKey="Bhandari B" first="Bal Raj" last="Bhandari">Bal Raj Bhandari</name><name sortKey="Br U, Norbert" sort="Br U, Norbert" uniqKey="Br U N" first="Norbert" last="Br U">Norbert Br U</name><name sortKey="Brainard, Diana M" sort="Brainard, Diana M" uniqKey="Brainard D" first="Diana M" last="Brainard">Diana M. Brainard</name><name sortKey="Davis, Mitchell" sort="Davis, Mitchell" uniqKey="Davis M" first="Mitchell" last="Davis">Mitchell Davis</name><name sortKey="Dvory Sobol, Hadas" sort="Dvory Sobol, Hadas" uniqKey="Dvory Sobol H" first="Hadas" last="Dvory-Sobol">Hadas Dvory-Sobol</name><name sortKey="Hyland, Robert H" sort="Hyland, Robert H" uniqKey="Hyland R" first="Robert H" last="Hyland">Robert H. Hyland</name><name sortKey="Lawitz, Eric" sort="Lawitz, Eric" uniqKey="Lawitz E" first="Eric" last="Lawitz">Eric Lawitz</name><name sortKey="Mchutchison, John G" sort="Mchutchison, John G" uniqKey="Mchutchison J" first="John G" last="Mchutchison">John G. Mchutchison</name><name sortKey="Nahass, Ronald G" sort="Nahass, Ronald G" uniqKey="Nahass R" first="Ronald G" last="Nahass">Ronald G. Nahass</name><name sortKey="Ruane, Peter J" sort="Ruane, Peter J" uniqKey="Ruane P" first="Peter J" last="Ruane">Peter J. Ruane</name><name sortKey="Stamm, Luisa M" sort="Stamm, Luisa M" uniqKey="Stamm L" first="Luisa M" last="Stamm">Luisa M. Stamm</name><name sortKey="Subramanian, G Mani" sort="Subramanian, G Mani" uniqKey="Subramanian G" first="G Mani" last="Subramanian">G Mani Subramanian</name><name sortKey="Svarovskaia, Evguenia" sort="Svarovskaia, Evguenia" uniqKey="Svarovskaia E" first="Evguenia" last="Svarovskaia">Evguenia Svarovskaia</name><name sortKey="Zhu, Yanni" sort="Zhu, Yanni" uniqKey="Zhu Y" first="Yanni" last="Zhu">Yanni Zhu</name></country><country name="Nouvelle-Zélande"><noRegion><name sortKey="Gane, Edward J" sort="Gane, Edward J" uniqKey="Gane E" first="Edward J" last="Gane">Edward J. Gane</name></noRegion><name sortKey="Stedman, Catherine A M" sort="Stedman, Catherine A M" uniqKey="Stedman C" first="Catherine A M" last="Stedman">Catherine A M. Stedman</name></country><country name="Canada"><noRegion><name sortKey="Willems, Bernard E" sort="Willems, Bernard E" uniqKey="Willems B" first="Bernard E" last="Willems">Bernard E. Willems</name></noRegion><name sortKey="Borgia, Sergio M" sort="Borgia, Sergio M" uniqKey="Borgia S" first="Sergio M" last="Borgia">Sergio M. Borgia</name><name sortKey="Feld, Jordan J" sort="Feld, Jordan J" uniqKey="Feld J" first="Jordan J" last="Feld">Jordan J. Feld</name><name sortKey="Shafran, Stephen D" sort="Shafran, Stephen D" uniqKey="Shafran S" first="Stephen D" last="Shafran">Stephen D. Shafran</name></country><country name="Géorgie (pays)"><noRegion><name sortKey="Workowski, Kimberly A" sort="Workowski, Kimberly A" uniqKey="Workowski K" first="Kimberly A" last="Workowski">Kimberly A. Workowski</name></noRegion><name sortKey="Pearlman, Brian" sort="Pearlman, Brian" uniqKey="Pearlman B" first="Brian" last="Pearlman">Brian Pearlman</name></country><country name="Allemagne"><region name="Berlin"><name sortKey="Berg, Thomas" sort="Berg, Thomas" uniqKey="Berg T" first="Thomas" last="Berg">Thomas Berg</name></region></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Agarwal, Kosh" sort="Agarwal, Kosh" uniqKey="Agarwal K" first="Kosh" last="Agarwal">Kosh Agarwal</name></region><name sortKey="Foster, Graham R" sort="Foster, Graham R" uniqKey="Foster G" first="Graham R" last="Foster">Graham R. Foster</name></country><country name="Australie"><noRegion><name sortKey="Dore, Gregory J" sort="Dore, Gregory J" uniqKey="Dore G" first="Gregory J" last="Dore">Gregory J. Dore</name></noRegion><name sortKey="Roberts, Stuart K" sort="Roberts, Stuart K" uniqKey="Roberts S" first="Stuart K" last="Roberts">Stuart K. Roberts</name><name sortKey="Thompson, Alexander J" sort="Thompson, Alexander J" uniqKey="Thompson A" first="Alexander J" last="Thompson">Alexander J. Thompson</name></country><country name="France"><noRegion><name sortKey="Asselah, Tarik" sort="Asselah, Tarik" uniqKey="Asselah T" first="Tarik" last="Asselah">Tarik Asselah</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D44 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000D44 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:28390869
|texte= Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:28390869" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |